Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Scientists reprogram triple-negative breast cancer cells to respond to tamoxifen

09.07.2010
Using a small molecule decoy, investigators funded by the Samuel Waxman Cancer Research Foundation have managed to block protein interactions and induce epigenetic reprogramming in human and mouse breast cancer cells, essentially changing the gene expression of breast cancer cells to behave in a more normal manner.

The research illustrates what may perhaps become an effective targeted epigenetic therapy in breast cancer. Interestingly, the targeted treatment showed exciting results in triple-negative breast cancer cells, reverting their function and appearance, and sensitizing them to tamoxifen and retinoids.

By introducing a small peptide, called the SID decoy, to interfere with protein binding in the Sin 3 PAH2 domain, scientists reduced the growth of triple-negative cancer cells by 80 percent. The decoy also blocked cancer cell invasion, which may shed light on preventing metastasis. The study was published in the June 29 print edition of the journal of the Proceedings of the National Academy of Sciences.

Triple-negative breast cancer is an aggressive form of breast cancer more commonly diagnosed in young women, African-American women and women with BRCA-1 mutated cancers, said medical oncologist Samuel Waxman, M.D., the study's senior author. Currently, the only treatment options that women with triple-negative breast cancer have are radiation therapy, surgery and chemotherapy. Women with triple-negative breast cancer do not respond to hormonal therapy or Herceptin and have a higher recurrence rate after chemotherapy.

"Hopefully, this breakthrough research means we can expand treatment options for women with triple-negative breast cancer and give them a chance at anti-estrogen hormonal therapy," said Dr. Waxman, a professor in the department of Hematology and Oncology at Mount Sinai Medical Center in New York City and the scientific director of the Samuel Waxman Cancer Research Foundation.

Arthur Zelent, Ph.D., a co-author of the study, said researchers plan to investigate small molecules that are predicted to have the same effect as the decoy peptide. "This could form the basis for a new class of targeted, epigenetic drugs in breast cancer," said Dr. Zelent, a team leader at The Institute of Cancer Research in the United Kingdom.

Elizabeth Woolfe, the executive director of the Triple Negative Breast Cancer Foundation, said though the study's results are too preliminary to make a clinical impact for cancer survivors today, she added, "The findings offer encouraging results that could lead to other promising research and the potential for new therapeutics for women facing triple-negative breast cancer."

About the Samuel Waxman Cancer Research Foundation

The Samuel Waxman Cancer Research Foundation is an international organization dedicated to curing and preventing cancer. The Foundation is a pioneer in cancer research, focusing on uncovering the causes of cancer and reprogramming cancer cells.

We dedicate ourselves to delivering tailored, minimally toxic treatments to patients. Our mission is to eradicate cancer by bridging the gap between lab science and the patient.

Through our collaborative group of world-class scientists, the Institute Without Walls, investigators share information and tools to speed the pace of cancer research. Since its inception in 1976, the SWCRF has awarded more than $70 million to support the work of more than 170 researchers across three continents.

Jenny Song | EurekAlert!
Further information:
http://www.waxmancancer.org

More articles from Life Sciences:

nachricht The birth of a new protein
20.10.2017 | University of Arizona

nachricht Building New Moss Factories
20.10.2017 | Albert-Ludwigs-Universität Freiburg im Breisgau

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Terahertz spectroscopy goes nano

20.10.2017 | Information Technology

Strange but true: Turning a material upside down can sometimes make it softer

20.10.2017 | Materials Sciences

NRL clarifies valley polarization for electronic and optoelectronic technologies

20.10.2017 | Interdisciplinary Research

VideoLinks
B2B-VideoLinks
More VideoLinks >>>